Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Mamo, D. Articles by Kapur, S. Search for Related Content PubMed Citation Articles by Mamo, D. Articles by Kapur, S. Schizophrenia Spectrum Disorders Atypical Neuroleptics PET Related Article

Differential Effects of Aripiprazole on D₂, 5-HT₂, and 5-HT_1A Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study

OBJECTIVE: Aripiprazole has a unique pharmacological profile that includes partial agonism at D₂ receptors, antagonism at 5-HT₂ receptors, and partial agonism at 5-HT_1A receptors. The authors conducted a positron emission tomography (PET) study to characterize the simultaneous effects of aripiprazole at the D₂, 5-HT₂, and 5-HT_1A receptors in patients with schizophrenia or schizoaffective disorder. METHOD: Twelve patients who had previously received antipsychotic treatment were randomly assigned to receive 10 mg, 15 mg, 20 mg, or 30 mg of aripiprazole. After at least 14 days of treatment, participants underwent high-resolution PET scans using [¹¹C]raclopride, [¹⁸F]setoperone, and [¹¹C]WAY100635. RESULTS: Very high occupancy was observed at striatal D₂ receptors (average putamen, 87%; caudate, 93%; and ventral striatum, 91%), lower occupancy at 5-HT₂ receptors (54%–60%), and even lower occupancy at 5-HT_1A receptors (16%). D₂ occupancy levels were significantly correlated with plasma drug concentrations, and even the lowest dose (10 mg) led to 85% D₂ occupancy. Extrapyramidal side effects were seen only in two of the four participants with occupancies exceeding 90%. CONCLUSIONS: Aripiprazole exhibits a unique occupancy profile as compared with other conventional and atypical antipsychotics. The threshold for response appears to be higher than 60%, extrapyramidal side effects appear to be uncommon even at occupancies that exceed the conventional extrapyramidal side effects threshold of 80%, and 5-HT₂ occupancy is lower than D₂ occupancy. Implications for aripiprazole’s mechanism of action are discussed.

Related Article:

In This Issue
Am J Psychiatry 2007 164: A36. [Full Text] [PDF]

This article has been cited by other articles:

				M. HAZRA, D. C. MAMO, and G. REMINGTON Adjunctive Versus Monotherapeutic Treatment for Schizophrenia: Addressing Antipsychotic Side Effects Am J Psychiatry, March 1, 2008; 165(3): 396 - 397. [Full Text] [PDF]

				M. POYUROVSKY, R. WEIZMAN, and A. WEIZMAN Aripiprazole's Receptor Pharmacology and Extrapyramidal Side Effects Am J Psychiatry, March 1, 2008; 165(3): 398 - 398. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us